Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
J Clin Oncol
; 41(12): 2238-2247, 2023 04 20.
Article
in En
| MEDLINE
| ID: mdl-36548927
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Lymphoma, Large B-Cell, Diffuse
/
Receptors, Chimeric Antigen
/
Antineoplastic Agents
Limits:
Adult
/
Humans
/
Middle aged
Language:
En
Journal:
J Clin Oncol
Year:
2023
Type:
Article
Affiliation country:
France